Foundayo vs. Oral Wegovy: Results, Dosing, and Risks
Compare Foundayo and oral Wegovy, including fasting rules, weight-loss results, side effects, interactions, cardiovascular indications, and pregnancy warnings.
WEIGHT MANAGEMENTTREATMENT OPTIONS
Sarina Helton, MSN, APRN, FNP-C, CAE-OM Founder, Optima Vida Healthcare
9/13/20269 min read
Foundayo vs. Oral Wegovy: Comparing Two Oral GLP-1 Medications
Foundayo and oral Wegovy are once-daily oral GLP-1 medications approved for long-term weight management in eligible adults. They activate the same receptor but contain different drugs and have important differences in administration, metabolism, interactions, pregnancy considerations, and FDA-approved indications.
The most practical distinction is administration:
Foundayo can be taken at any time of day, with or without food, and without special water restrictions.
Oral Wegovy is taken in the morning on an empty stomach with up to four ounces of plain water, followed by at least a 30-minute wait before food, beverages, or other oral medications.
Both medications produced clinically meaningful average weight reduction in clinical trials. They have not been adequately compared in a randomized head-to-head obesity trial, so separate study results cannot establish that one is more effective than the other.
What Is Foundayo?
Foundayo is the brand name for orforglipron, a nonpeptide small-molecule GLP-1 receptor agonist.
Its chemical structure allows absorption as a conventional tablet without the specialized fasting and water conditions required for oral semaglutide.
The FDA labeling describes Foundayo as:
A once-daily oral medication
Taken at any time of day
Taken with or without food
Taken without special water restrictions
Swallowed whole
Foundayo has no administration-related waiting period before food or other oral medications. However, it has clinically important metabolic, transporter, and absorption interactions that still require medication review.
Read Foundayo for Weight Loss for a detailed review of orforglipron.
What Is Oral Wegovy?
Oral Wegovy contains semaglutide, the same active drug found in Wegovy injections.
Semaglutide is a peptide. Wegovy tablets contain the absorption enhancer salcaprozate sodium, also called SNAC, which helps semaglutide cross the stomach lining. Even with SNAC, oral semaglutide has low and variable absorption that can be affected by food, beverages, and other oral medications.
The FDA label specifies that Wegovy tablets are:
Taken once daily in the morning
Taken on an empty stomach
Taken with plain water only, up to four ounces
Followed by at least a 30-minute wait before food, beverages, or other oral medications
Swallowed whole rather than split, crushed, chewed, or dissolved
These administration conditions are part of the product labeling because they affect drug absorption.
See Oral Wegovy for Weight Loss for the full semaglutide-tablet overview.
Who Meets the FDA-Labeled Weight-Management Population?
Both medications are approved with reduced-calorie nutrition and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with:
Obesity, or
Overweight and at least one weight-related medical condition
Weight-related conditions can include hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, and cardiovascular disease.
Neither Foundayo nor oral Wegovy is currently approved for pediatric weight management or specifically for treatment of type 2 diabetes.
Eligibility is explained further in Who Qualifies for Prescription Weight-Loss Medication?.
Their Additional FDA Indications Differ
Foundayo is currently approved for chronic weight reduction and long-term maintenance in eligible adults. It does not have separate FDA indications for cardiovascular-risk reduction, obstructive sleep apnea, MASH, or diabetes treatment.
Oral Wegovy is approved for:
Chronic weight reduction and long-term maintenance in eligible adults
Reduction of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity
The cardiovascular indication involves cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.
Wegovy’s pediatric obesity and MASH indications apply to the injection—not the tablets.
The presence of an additional indication can affect clinical evaluation and insurance coverage, but it does not automatically make a medication appropriate for every person with cardiovascular risk factors.
How Do They Work?
Both medications activate GLP-1 receptors. This can reduce appetite and food intake, increase fullness, enhance glucose-dependent insulin release, reduce inappropriate glucagon secretion, and delay gastric emptying.
Neither medication directly “burns fat.” Weight reduction occurs primarily through sustained reductions in energy intake.
The drugs are chemically and pharmacokinetically different. Their milligram strengths cannot be compared directly, and a higher milligram number does not indicate a stronger medication.
Available Strengths and Escalation
Foundayo is available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg tablets. Its FDA-approved regimen uses staged escalation with at least 30 days at each step. The labeled maximum is 17.2 mg once daily, although certain drug interactions lower the maximum.
Oral Wegovy is available in 1.5 mg, 4 mg, 9 mg, and 25 mg tablets. Its approved regimen also uses staged 30-day escalation. The labeled maintenance dose is 25 mg once daily.
This overview describes the approved structures without providing an individualized dosing plan. Treatment response, tolerability, drug interactions, interruption history, and the product label affect dose decisions.
Learn more in Increasing Your GLP-1 Dose.
Weight-Loss Results in Separate Clinical Trials
Foundayo Trial
In a 72-week trial involving adults without type 2 diabetes, average observed weight reductions were:
7.4% with Foundayo 5.5 mg
8.3% with Foundayo 9 mg
11.1% with Foundayo 17.2 mg
2.1% with placebo
A different statistical analysis estimating results if participants remained on assigned treatment as planned produced an average of approximately 12.4% at the highest dose.
Oral Wegovy Trial
In a 64-week trial involving adults without type 2 diabetes, average weight reduction was:
13.6% with oral Wegovy 25 mg
2.4% with placebo
These numbers may make oral Wegovy appear to produce greater average weight loss, but the trials differed in treatment duration, participants, discontinuation patterns, and statistical methods.
A numerical comparison across separate trials is descriptive—not proof of superiority. Individual results also vary substantially.
Administration Convenience
Foundayo has fewer administration restrictions. This may matter when someone eats or drinks soon after waking, takes several morning medications, works rotating shifts, or has difficulty maintaining a fasting routine.
Oral Wegovy requires a consistent fasting window and separation from other oral medications. For some people this routine is manageable; for others it may create adherence challenges.
Convenience can influence treatment sustainability, but it is only one part of clinical selection.
Common Adverse Effects
Both medications commonly cause gastrointestinal effects, including:
Nausea
Vomiting
Diarrhea
Constipation
Abdominal discomfort
Indigestion
Reflux
Burping
Abdominal distension
Reduced appetite
Headache, fatigue, hair loss associated with weight reduction, dizziness, and increased resting heart rate have also been reported.
Gastrointestinal symptoms are often more noticeable during dose escalation and may decrease over time. Severe nausea or vomiting does not establish a better treatment response. Related information is available in When to contact your provider and Nausea on GLP-1 Medications.
Both labels warn about pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration and acute kidney injury, serious hypersensitivity reactions, hypoglycemia with insulin or certain insulin secretagogues, diabetic-retinopathy complications, and pulmonary aspiration during general anesthesia or deep sedation.
Neither medication is recommended in severe gastroparesis.
Warning Signs
Severe or persistent abdominal pain, repeated vomiting, inability to retain fluids, markedly reduced urination, fainting, confusion, breathing difficulty, facial or throat swelling, new visual symptoms, or right-upper-abdominal pain with fever or jaundice may indicate a need for prompt or emergency evaluation.
These symptoms can have several causes and should not automatically be attributed to a routine GLP-1 effect.
Thyroid C-Cell Tumor Boxed Warning
Both medications carry an FDA boxed warning concerning the potential risk of thyroid C-cell tumors.
They are contraindicated in people with:
A personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2
Each medication is also contraindicated after a serious hypersensitivity reaction to that drug or its ingredients.
It is unknown whether either medication causes medullary thyroid carcinoma in humans. Both labels state that routine calcitonin monitoring or thyroid ultrasound has uncertain value for early detection solely because someone uses the medication.
Read The Thyroid C-Cell Tumor Warning and GLP-1 Medications for additional context.
Foundayo Drug Interactions
Foundayo has more metabolism-based interactions than oral Wegovy.
Orforglipron is a substrate of CYP3A4 and CYP2J2 and is transported by P-glycoprotein, OATP1B1, and OATP1B3.
The Foundayo label states that:
Strong CYP3A4 inhibitors can increase exposure and lower the labeled maximum Foundayo dose to 9 mg once daily.
The label advises against combined use with strong CYP3A4 inhibitors that also inhibit OATP1B, such as ritonavir.
The label advises against combined use with strong CYP3A4 inducers because they can substantially reduce exposure.
Simvastatin is limited to 20 mg once daily when used with Foundayo.
Insulin or sulfonylurea therapy may require clinician-managed reassessment because hypoglycemia risk increases.
Foundayo also delays gastric emptying and may affect absorption of other oral medications.
Learn about CYP3A4 medications and Foundayo
Oral Wegovy Drug-Absorption Considerations
Oral Wegovy does not have Foundayo’s CYP3A4 and OATP1B interaction pattern. Its principal medication-timing issue is the required fasting administration and 30-minute separation from other oral drugs.
Semaglutide also delays gastric emptying and can affect oral drug absorption. The clinical importance depends on the medication, particularly when precise or rapid absorption matters.
Neither product has a universal spacing strategy that replaces medication-specific review.
Foundayo and Oral Hormonal Contraceptives
Foundayo delays gastric emptying and may reduce oral hormonal contraceptive effectiveness. The effect has not been directly evaluated in a clinical trial.
The Foundayo label advises use of a nonoral contraceptive method or an added barrier method for:
30 days after Foundayo initiation
30 days after every dose escalation
Nonoral hormonal contraception is not expected to be affected.
Oral Wegovy does not carry the same specific contraceptive instruction. Pregnancy potential can still change with weight reduction and improved ovulation in some people.
Pregnancy Considerations
Neither medication is used for weight reduction during pregnancy.
The Foundayo label includes pregnancy-specific discontinuation instructions but does not specify a preconception washout interval.
Because semaglutide has a long half-life, the Wegovy label states that treatment for weight reduction or cardiovascular-risk reduction is discontinued at least two months before a planned pregnancy.
These are labeling differences, not individualized pregnancy or contraceptive guidance.
Can Foundayo and Oral Wegovy Be Combined?
The product labeling does not recommend either medication in combination with another GLP-1 receptor agonist or another product containing the same active drug.
The safety and effectiveness of combining Foundayo with oral Wegovy—or with another semaglutide, tirzepatide, liraglutide, or GLP-1 product—have not been established. Overlapping adverse effects may increase risk. See Can GLP-1 Medications Be Combined?.
Can Patients Switch Between Them?
There is no FDA-approved milligram conversion between orforglipron and semaglutide.
A clinician-managed transition may consider the current medication and dose, duration of treatment, prior adverse effects, appetite and weight response, other medications, diabetes treatment, cardiovascular history, oral contraception, pregnancy potential, and the pharmacokinetics of the outgoing drug.
This article does not provide a switching schedule.
Factors Clinicians May Consider
Treatment selection may involve:
FDA-labeled indication
Expected benefits and limitations
Cardiovascular history
Contraindications
Gastrointestinal history
Medication interactions
Oral contraception and pregnancy considerations
Ability to follow fasting administration requirements
Preference for simpler administration
Previous response to semaglutide or another GLP-1 medication
Insurance coverage, cost, and long-term access
Neither medication is universally “better.” The practical fit depends on the complete clinical and access context. The broader process is discussed in How Are Anti-Obesity Medications Selected?.
Frequently Asked Questions
Which Is Easier to Take: Foundayo or Oral Wegovy?
Foundayo has fewer administration restrictions because it may be taken with or without food and does not require a specific water volume or waiting period. Oral Wegovy requires morning fasting administration with up to four ounces of plain water and at least a 30-minute wait.
Which Produced More Weight Loss in Clinical Trials?
Oral Wegovy produced a 13.6% average reduction in its 64-week study, while the highest Foundayo dose produced an 11.1% observed average reduction in its separate 72-week study. Because the medications were not compared directly, these percentages do not establish superiority.
Are Foundayo and Oral Wegovy the Same Drug?
No. Foundayo contains orforglipron, a nonpeptide small molecule. Oral Wegovy contains peptide-based semaglutide combined with the absorption enhancer SNAC.
Which Has a Cardiovascular-Risk Reduction Indication?
Oral Wegovy is approved to reduce major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. Foundayo does not currently have that indication.
Can Foundayo and Oral Wegovy Be Taken Together?
No approved evidence supports combining them. Both labels advise against use with another GLP-1 receptor agonist.
The Bottom Line
Foundayo and oral Wegovy are both once-daily oral GLP-1 medications, but they are not interchangeable.
Foundayo has simpler administration because it has no fasting or special water requirements. It also has more CYP3A4 and transporter interactions and carries a specific oral-contraception precaution.
Oral Wegovy has stricter administration requirements and an additional cardiovascular-risk-reduction indication for eligible adults. It produced a 13.6% average weight reduction in its separate 64-week trial, while the highest Foundayo dose produced an 11.1% observed average reduction in a separate 72-week trial.
Those separate trials do not prove that oral Wegovy is superior. Medication selection requires consideration of indication, medical history, interactions, pregnancy potential, administration routine, expected benefit, adverse effects, cost, and long-term sustainability.
Written by and clinically reviewed for accuracy by:
Sarina Helton, MSN, APRN, FNP-C, CAE-OM
Sarina Helton, MSN, APRN, FNP-C, CAE-OM, is a board-certified family nurse practitioner and founder of Optima Vida Healthcare. Her clinical focus includes obesity medicine, medical weight management, metabolic health, hormone-related concerns, sexual health, hair loss, and evidence-based telehealth care.
Last medically reviewed: August 2026
Learn More About Medical Weight Management
At Optima Vida Healthcare (OVH), weight-management care is individualized according to health history, previous treatment, medication response, side effects, goals, and long-term needs.
Treatment may include Foundayo, oral Wegovy, another GLP-1 medication, or a non-GLP-1 option when clinically appropriate.
Start an OVH Weight-Management Evaluation →
Visit ovhmed.com for more information →
Prescription medication is not guaranteed. Prescribing decisions are made by a licensed healthcare professional after an appropriate clinical evaluation.
Sarina Helton, MSN, APRN, FNP-C, CAE-OM
Founder, Optima Vida Healthcare
Educational Disclaimer
This article is provided for general educational purposes only. It does not provide individualized medical advice, recommend combining, switching, restarting, stopping, or changing the dose of a GLP-1 medication, provide a contraceptive or pregnancy plan, or replace urgent or emergency evaluation.
Information reviewed August 31, 2026.
Sources
U.S. Food and Drug Administration. Foundayo Prescribing Information. Revised July 2026. FDA label
U.S. Food and Drug Administration. Wegovy Prescribing Information. Revised February 2026. FDA label
Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 2025;393:1796–1806. Study
Wilding JPH, et al. Once-Weekly Semaglutide in Adults With Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. Study
Eli Lilly and Company. Foundayo. Manufacturer information
Foundayo vs. Oral Wegovy: Results, Dosing, and Risks
Compare Foundayo and oral Wegovy, including fasting rules, weight-loss results, side effects, interactions, cardiovascular indications, and pregnancy warnings.
/foundayo-vs-oral-wegovy
Foundayo vs oral Wegovy
orforglipron vs semaglutide, oral GLP-1 comparison, Foundayo weight loss, oral Wegovy results, Foundayo interactions, Wegovy tablets
Foundayo and oral Wegovy are daily GLP-1 pills with different fasting rules, interactions, indications, trial results, and pregnancy considerations.
Foundayo and oral Wegovy tablet comparison for weight management
Article with FAQPage markup
Contact
Optima Vida Healthcare, LLC
Telehealth medical services
support@ovhmed.com
© 2026 Optima Vida Healthcare, LLC. All rights reserved.